Clinical trials: Anticoagulant
Deep Vein Thrombosis, Superficial Thrombophlebitis
DOACT Algorithm Versus AI-Based Decision Models in Oral Anticoagulant Therapy for Vascular Patients
Study using a decision algorithm for the application of an oral anticoagulant calculator in vascular diseases, aimed at validating a clinical decision-support tool for conditions such as deep vein thrombosis, superficial…
- Conditions
- Deep Vein Thrombosis, Superficial Thrombophlebitis, Pulmonary Thromboembolisms, Clinical Decision Support Systems
- Trial name
- DOACT (NCT07290608)
- Testing
- DOACT algorithm, No algorithm, LLM-based tools
- Where
- Brazil
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- ITALO EUGENIO SOUZA GADELHA DE ABREU
Cancer, Rivaroxaban
Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin
The Valeria trial will provide high-quality evidence regarding the efficacy and safety of oral rivaroxaban in thromboprophylaxis after gynecological pelvic cancer surgery in comparison with standard parenteral enoxaparin.
- Conditions
- Cancer, Rivaroxaban, Venous Thromboembolism, Thromboprophylaxis
- Trial name
- VALERIA (NCT04999176)
- Testing
- Rivaroxaban, Enoxaparin
- Where
- Brazil
- Volunteers
- 440 people
- Sponsor
- André Luiz Malavasi Longo de Oliveira
Anticoagulant, Apixaban
A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
A prospective cohort study to determine whether a high body weight (BMI equal to or greater than 35 kg / m 2) has an effect on anticoagulant Apixaban level in the blood of patients with atrial fibrillation.
- Conditions
- Anticoagulant, Apixaban, Obesity
- Trial name
- NCT03893591
- Testing
- Anti Xa levels
- Where
- Israel
- Volunteers
- 82 people
- Sponsor
- HaEmek Medical Center, Israel
Atrial High Rate Episodes
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes
NOAH is an investigator-initiated, prospective, parallel-group, double-blind, randomised, multi-centre trial. The objective of the trial is to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current…
- Trial name
- NOAH (NCT02618577)
- Testing
- Edoxaban, ASA
- Where
- 18 sites in Austria, Belgium and 16 more
- Volunteers
- 2,608 people
- Sponsor
- Atrial Fibrillation Network
Healthy
Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers
To demonstrate the pharmacodynamic (PD) equivalence of enoxaparin Rovi (100 mg/mL) 100-mg SC injection to Clexane® (100 mg/mL) 100-mg SC injection in healthy volunteers.
- Trial name
- NCT03363477
- Testing
- Enoxaparin, Clexane
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Rovi Pharmaceuticals Laboratories
Bleeding
Incidence of Late Haemorrhage After Invasive Gastroenterological Endoscopic Manoeuvre in Patients Treated With Anticoagulants Compared to Non-anticoagulated Patients
Patients on oral anticoagulant therapy with vitamin K antagonists (AVKs; warfarin and acenocoumarol) and direct oral anticoagulants (DOACs; apixaban, dabigatran, edoxaban and rivaroxaban), are advised to consider discontinuing…
- Trial name
- EMOSCOPIO (NCT07019077)
- Where
- Italy
- Volunteers
- 4,719 people
- Sponsor
- Centro Cardiologico Monzino
Venous Thromboembolism
Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism
The main objective of the study is to develop or validate a clinical prediction rule for major bleeding in patients on oral anticoagulant therapy who have been safely anticoagulated without bleeding or venous thromboembolism…
- Trial name
- NCT00788736
- Where
- 12 sites in United States, Canada and 1 more
- Volunteers
- 2,537 people
- Sponsor
- Ottawa Hospital Research Institute
Atrial Fibrillation, Anticoagulant Adverse Reaction
Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation
In this clinical trial, Rivaroxaban of standard dose (20mg) and reduced dose (15mg) will be administeted in non-valvular atrial fibrillation patients without severe renal dysfunction.
- Trial name
- REVISE-AF (NCT06187311)
- Testing
- Rivaroxaban 20 MG, Rivaroxaban 15 MG
- Where
- South Korea
- Volunteers
- 940 people
- Sponsor
- Korea University Anam Hospital
Cardiovascular Disease
Sources of the Variability of the Response to Fluindione in Elderly Patients (PREPA)
We propose to study the pharmacokinetic (PK) and pharmacodynamic (PD) components of the response to fluindione, the main oral anticoagulant used in France, in patients over 80.
- Trial name
- NCT00313469
- Where
- 2 sites in France
- Volunteers
- 152 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hemophilia A
Long-term Anticoagulation in a Patient With Severe Hemophilia A
To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII)…
- Trial name
- HAAC (NCT07314983)
- Where
- France
- Volunteers
- 1 people
- Sponsor
- University Hospital, Strasbourg, France
Severe Trauma Patient, Venous Thromboembolism
Intermediate Versus Standard Dose Enoxaparin to Prevent Venous Thromboembolism in Severe Trauma Patients: a Multicenter Double Blind Randomised Controlled Trial
Venous thromboembolism is a frequent issue in severe trauma patients. Guidelines for venous thromboembolism prevention include the use of pharmacological thromboprophylaxis, mainly with low-molecular-weight heparin, and/or…
- Trial name
- HEPTRAUMA (NCT07506473)
- Testing
- Enoxaparin standard dose, Enoxaparin intermediate dose
- Where
- 17 sites in France
- Volunteers
- 540 people
- Sponsor
- University Hospital, Grenoble
Endstage Renal Disease, Direct Oral Anticoagulants (DOACs)
Effect of Apiban Therapy on AVF Maturation in ESRD Patients
End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis [1].
- Conditions
- Endstage Renal Disease, Direct Oral Anticoagulants (DOACs), Arteriovenous Fistula, Arteriovenous Fistula Occlusion
- Trial name
- NCT07559942
- Testing
- Apixaban
- Where
- Pakistan
- Volunteers
- 190 people
- Sponsor
- Combined military hospital lahore
Respiratory Distress Syndrome, Adult, Extracorporeal Membrane Oxygenation
PGE1 as Additive Anticoagulant in ECMO-Therapy
Bleeding complications and thromboembolic complications are frequent during extracorporeal membrane oxygenation (ECMO). Retrospective data suggest that platelet inhibition using prostaglandins, in this case PGE1, may reduce…
- Trial name
- ECMO_PGE1 (NCT02895373)
- Testing
- Alprostadil, 0.9% sodium chloride solution
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Thomas Staudinger
Venous Thrombosis
Study of Arixtra (Fondaparinux Sodium) to Prevent Blood Clots in Women Undergoing Abdominopelvic Surgery for Likely Gynecologic Malignancy
This is a randomized trial to compare intermittent compression devices with or without post-operative Arixtra (fondaparinux sodium) in women undergoing major abdominal surgery for known or presumed gynecologic malignancies.
- Trial name
- NCT00539942
- Testing
- Arixtra (fondaparinux sodium), Intermittent compression devices (ICD)
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Covid19, Pneumonia
Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection
Viral infections provoke the systemic inflammatory response and cause an imbalance between the procoagulant and anticoagulant homeostatic mechanisms.
- Conditions
- Covid19, Pneumonia, Coagulation Disorder, Pulmonary Embolism
- Trial name
- NCT04508439
- Testing
- Enoxaparin
- Where
- Mexico
- Volunteers
- 130 people
- Sponsor
- Hospital Regional de Alta especialidad de Ixtapaluca
DOAC Eligible Subjects
Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System
Observational trial to evaluate the effectiveness of the TEG6s DOAC cartridge to detect and classify the presence of DOAC drugs in a subject.
- Trial name
- NCT02798328
- Testing
- TEG6s DOAC Cartridge
- Where
- 4 sites in United States
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
Acute Intracranial Hemorrhage
Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual care in patients with intracranial hemorrhage anticoagulated with a direct oral FXa anticoagulant
- Trial name
- NCT03661528
- Testing
- andexanet alfa, Usual Care
- Where
- 142 sites in United States, Austria and 22 more
- Volunteers
- 530 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Angina, Stable, Angina, Unstable
Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy
The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) has higher…
- Conditions
- Angina, Stable, Angina, Unstable, Anticoagulants
- Trial name
- COBRA-REDUCE (NCT02594501)
- Testing
- COBRA PzF, Drug Eluting Stent
- Where
- 48 sites in United States, Belgium and 6 more
- Volunteers
- 996 people
- Sponsor
- CeloNova BioSciences, Inc.
Ischemia, Stroke
Edoxaban for TIA and Acute Minor Stroke
Transient ischemic attack (TIA) or minor ischemic stroke has a high risk of early recurrent stroke. As the golden standard, aspirin effect modestly on acute ischemic stroke, and slightly increase the risk of intracerebral…
- Conditions
- Ischemia, Stroke, Cerebral Infarction
- Trial name
- NCT02221102
- Testing
- Aspirin, edoxaban
- Where
- China
- Volunteers
- 3,700 people
- Sponsor
- Xijing Hospital
Acute Respiratory Failure, SARS CoV 2 Infection
Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients
Coronavirus Disease (COVID-19) is characterized by a hypercoagulable state, sometimes difficult to be managed with heparin. Bivalirudin, a member of the direct thrombin inhibitor drug class, offers potential advantages compared…
- Conditions
- Acute Respiratory Failure, SARS CoV 2 Infection, Anticoagulants
- Trial name
- NCT05334654
- Testing
- Enoxaparin Sodium, Bivalirudin
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University Magna Graecia